# Abivax SA American (ABVX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $114.79, market value $10.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Abivax SA American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 18.2×**. The shares trade at 18.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.1%** (5-yr avg -18.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -73.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -72.5%**. Earnings per share fell 72.5%.

## Financial health
- **Current ratio: 8.75** (quick 8.75). Current assets cover the next year's liabilities 8.75 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Abivax SA American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 34.2%** (YTD -14.9%, 3-mo 13.1%). The shares are up 34.2% over twelve months including dividends.
- **From 52-week high: -22.9%** (64.4% above the low). Trading 23% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.00** (volatility 85%). Beta of 1.00 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABVX · Page: https://foliofundamentals.com/stocks/abvx

Not investment advice.